Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2020-05-08 Earnings Release
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2020, reporting the results of operations and financial condition for the quarter ended March 31, 2020. It specifically states that the company issued a press release announcing its quarterly results, and the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of the earnings information. The length is 3393 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2020-05-08 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-08 English
FORM 3 SUBMISSION
Director's Dealing
2020-04-23 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 16, 2020, by Spero Therapeutics, Inc. The key content is the appointment of a new director, Scott Jackson, to the Board of Directors, including details about his background, independence, and compensation. There is no financial data or report content; rather, it is an announcement of a change in the company's board. This fits the category of Board/Management Information (MANG). The document length is 6185 characters, which is sufficient for a detailed announcement but does not contain financial statements or earnings data. Therefore, the correct classification is MANG with high confidence.
2020-04-16 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC. It registers additional shares under an employee stock incentive plan, specifically the 2017 Stock Incentive Plan. The document includes details about the shares to be registered, the plan, and signatures of company officers. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital market filing related to share issuance under a stock plan. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS.
2020-03-19 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 16, 2020, by Spero Therapeutics, Inc. It announces the issuance of a press release regarding the company's financial results for the fourth quarter and full year ended December 31, 2019. The document itself does not contain the financial results or detailed financial statements but rather furnishes the press release as an exhibit. The text explicitly states that the information is not "filed" for certain regulatory purposes and is a current report announcing the results. Given the short length (3426 characters) and the nature of the content (announcement of results via press release), this is an Earnings Release (ER) type filing, which is the initial announcement of quarterly or periodical financial results with key highlights only, not the full annual report or detailed financial statements.
2020-03-16 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.